Research Analysts’ Recent Ratings Updates for Rocket Pharmaceuticals (RCKT)

Several brokerages have updated their recommendations and price targets on shares of Rocket Pharmaceuticals (NASDAQ: RCKT) in the last few weeks:

• 10/8/2026 – Rocket Pharmaceuticals was upgraded by The Goldman Sachs Group, Inc. from “sell” to “neutral”. They now have a $4.00 price target on the stock, up from $3.00.
• 10/7/2026 – Rocket Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/7/2026 – Rocket Pharmaceuticals had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $2.95 price target on the stock.
• 10/7/2026 – Rocket Pharmaceuticals had its price target lowered by Leerink Partners from $7.00 to $4.00. They now have a “market perform” rating on the stock.
• 10/7/2026 – Rocket Pharmaceuticals had its “outperform” rating reaffirmed by Wedbush.
• 10/7/2026 – Rocket Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $11.00 price target on the stock.
• 9/16/2026 – Rocket Pharmaceuticals had its “outperform” rating reaffirmed by Wedbush. They now have a $15.00 price target on the stock.
• 9/16/2026 – Rocket Pharmaceuticals was upgraded by Needham & Company LLC from “hold” to “buy”. They now have a $9.00 price target on the stock.
• 9/15/2026 – Rocket Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $11.00 price target on the stock.
• 9/1/2026 – Rocket Pharmaceuticals is now covered by Chardan Capital. They set a “buy” rating and a $11.00 price target on the stock.

Insider Buying and Selling

In related news, General Counsel Martin Wilson sold 75,364 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $3.40, for a total value of $256,237.60. Following the sale, the general counsel owned 598,489 shares of the company’s stock, valued at $2,034,862.60. The trade was a 11.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Christopher Stevens sold 36,658 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total value of $128,303.00. Following the completion of the sale, the chief operating officer owned 505,784 shares in the company, valued at $1,770,244. This trade represents a 6.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 125,977 shares of company stock worth $432,273 over the last ninety days. Company insiders own 21.30% of the company’s stock.

Rocket Pharmaceuticals, Inc (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses both ex vivo hematopoietic stem cell gene therapy and in vivo adeno-associated virus (AAV) gene therapy approaches to address conditions with limited or no effective treatment options.

Rocket’s development programs have included marnetegragene autotemcel (RP-L102) for leukocyte adhesion deficiency-I, a rare inherited immune disorder; RP-A501 for Danon disease, a genetic heart condition; RP-A601 for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations; and RP-L301 for pyruvate kinase deficiency, an inherited blood disorder.